The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited. A real-world analysis of ...
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...
Bridging therapies used in trials testing CAR-T therapies. Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials.
In patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intolerant to ibrutinib or acalabrutinib, zanubrutinib demonstrated favorable tolerability with only 40% of ibrutinib ...
Wellbeing Magazine on MSN
Women’s health awareness: Understanding the CLL BTK inhibitor
The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results